WuXi Biologics Authorizes Exelixis to Expand Oncology Biological Drug Production, an Industrial Info Market Brief
WuXi Biologics Authorizes Exelixis to Expand Oncology Biological Drug Production, an Industrial Info Market Brief
Attachment: A
WuXi Biologics has authorized Exelixis exclusively to expand its oncology biological drug production. WuXi AppTec, which includes WuXi Biologics, has 14 plants, with half in the U.S. and half in China.
WuXi AppTec has invested more than $707.4 million in China to construct or upgrade four plants since 2020.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021